Skip to main content

Table 2 Summary of adverse events in the 20 patients receiving CAR T cell infusion

From: Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia

TEAEs (N = 20) Any grade (%) Grades 3–4 (%) Grade 5 (%)
Cytokine release syndrome 95 45 0
Neurologic event 65 30 10
Hematologic event
 Thrombocytopenia 95 90 0
 Anemia 100 70 0
 Neutropenia 100 100 0
Non-hematologic event
 Diarrhea 50 0 0
 Abdominal pain 15 0 0
 Insomnia 5 0 0
 Headache or dizziness 20 0 0
 Muscle or bone pain 25 0 0
 Capillary leak syndromes 30 0 0
 Infection 20 20 0
 Hypotension 25 5 0
 Hypoxemia 30 5 0
 Elevated aminotransferases 60 5 0
 Elevated blood bilirubin 60 5 0
 Elevated creatinine 0 0 0
 Cardiovascular disorders 0 0 0
 Hyponatremia 20 0 0
 Hypokalemia 55 0 0
 Hypocalcemia 65 0 0
 Hypoalbuminemia 50 0 0
 Hypofibrinogenemia 60 30 0
 Prolonged activated partial thromboplastin time 15 0 0